QuidelOrtho Corp
QDEL22.810USD
-0.210-0.91%
Cierre 08/01, 16:00（ET）Cotizaciones retrasadas 15 min
1.54BCap. mercado
PérdidaP/E TTM
Más Datos de QuidelOrtho Corp Compañía
QuidelOrtho Corporation provides in vitro diagnostics, developing and manufacturing intelligent solutions. The Company specializes in immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its business units include labs, molecular diagnostics, point of care and transfusion medicine. Under the labs business unit, its product categories include virology & bioassays, specialty products, VITROS platform and immunodiagnostics. Under the molecular diagnostics business unit, its product categories include Lyra, Solana and Savanna. Under the point of care business unit, its product categories include rapid immunoassay and cardiometabolic immunoassay. Under the transfusion medicine business unit, its product categories include immunohematology and donor screening. It provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics and Ortho Optix.
Información de la empresa
Símbolo de cotizaciónQDEL
Nombre de la empresaQuidelOrtho Corp
Fecha de salida a bolsaFeb 01, 1991
Fundada en2021
Director ejecutivoMr. Brian J. Blaser
Número de empleados6600
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 01
Dirección9975 Summers Ridge Road
CiudadSAN DIEGO
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal92121
Teléfono18585521100
Sitio Webhttps://www.quidelortho.com/
Símbolo de cotizaciónQDEL
Fecha de salida a bolsaFeb 01, 1991
Fundada en2021
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Kenneth F. Buechler, Ph.D.
Dr. Kenneth F. Buechler, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
104.41K
+9.68%
Dr. Matthew W. Strobeck, Ph.D.
Dr. Matthew W. Strobeck, Ph.D.
Independent Director
Independent Director
72.55K
+7.29%
Mr. Joseph M. Busky
Mr. Joseph M. Busky
Chief Financial Officer
Chief Financial Officer
33.58K
+75.18%
Ms. Michelle A. Hodges, J.D.
Ms. Michelle A. Hodges, J.D.
Senior Vice President, Corporate Secretary, Chief Legal Officer
Senior Vice President, Corporate Secretary, Chief Legal Officer
29.21K
+25.00%
Mr. Edward L. (Ed) Michael
Mr. Edward L. (Ed) Michael
Independent Director
Independent Director
21.35K
+35.98%
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
14.27K
+75.49%
Mr. Brian J. Blaser
Mr. Brian J. Blaser
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
11.45K
--
Mr. John R. Chiminski
Mr. John R. Chiminski
Independent Director
Independent Director
2.52K
--
Sergio Gadaleta
Sergio Gadaleta
Senior Vice President - Clinical and Regulatory Affairs
Senior Vice President - Clinical and Regulatory Affairs
--
--
Devon Burek
Devon Burek
Senior Vice President - Global Quality
Senior Vice President - Global Quality
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Kenneth F. Buechler, Ph.D.
Dr. Kenneth F. Buechler, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
104.41K
+9.68%
Dr. Matthew W. Strobeck, Ph.D.
Dr. Matthew W. Strobeck, Ph.D.
Independent Director
Independent Director
72.55K
+7.29%
Mr. Joseph M. Busky
Mr. Joseph M. Busky
Chief Financial Officer
Chief Financial Officer
33.58K
+75.18%
Ms. Michelle A. Hodges, J.D.
Ms. Michelle A. Hodges, J.D.
Senior Vice President, Corporate Secretary, Chief Legal Officer
Senior Vice President, Corporate Secretary, Chief Legal Officer
29.21K
+25.00%
Mr. Edward L. (Ed) Michael
Mr. Edward L. (Ed) Michael
Independent Director
Independent Director
21.35K
+35.98%
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
14.27K
+75.49%
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2025Q1
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Labs
373.10M
53.85%
Point-of-Care
170.80M
24.65%
Immunohematology
128.50M
18.55%
Donor Screening
12.80M
1.85%
Molecular Diagnostic Solutions
7.60M
1.10%
Por regiónUSD
Nombre
Ganancia
Proporción
North America
406.70M
58.70%
Other
122.20M
17.64%
EMEA
88.90M
12.83%
China
75.00M
10.83%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Labs
373.10M
53.85%
Point-of-Care
170.80M
24.65%
Immunohematology
128.50M
18.55%
Donor Screening
12.80M
1.85%
Molecular Diagnostic Solutions
7.60M
1.10%
Estadísticas de accionistas
Actualizado: mié., 16 de jul
Actualizado: mié., 16 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
T. Rowe Price Investment Management, Inc.
16.93%
The Vanguard Group, Inc.
11.53%
BlackRock Institutional Trust Company, N.A.
11.17%
Rubric Capital Management LP
6.86%
Invesco Advisers, Inc.
5.33%
Other
48.19%
Accionistas
Accionistas
Proporción
T. Rowe Price Investment Management, Inc.
16.93%
The Vanguard Group, Inc.
11.53%
BlackRock Institutional Trust Company, N.A.
11.17%
Rubric Capital Management LP
6.86%
Invesco Advisers, Inc.
5.33%
Other
48.19%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
60.73%
Investment Advisor/Hedge Fund
33.26%
Hedge Fund
15.22%
Research Firm
2.15%
Pension Fund
1.27%
Sovereign Wealth Fund
1.18%
Individual Investor
0.92%
Bank and Trust
0.68%
Family Office
0.36%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
682
78.07M
115.45%
-20.91M
2025Q1
726
76.59M
113.26%
-21.60M
2024Q4
747
75.07M
111.30%
-13.02M
2024Q3
744
73.58M
109.44%
-4.02M
2024Q2
767
70.18M
104.79%
-7.57M
2024Q1
799
67.05M
100.24%
-5.28M
2023Q4
828
68.21M
102.09%
-2.95M
2023Q3
842
70.19M
105.17%
-4.01M
2023Q2
860
68.99M
103.61%
-6.94M
2023Q1
894
68.68M
103.29%
-6.80M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
T. Rowe Price Investment Management, Inc.
11.45M
16.93%
+208.36K
+1.85%
Mar 31, 2025
The Vanguard Group, Inc.
6.72M
9.94%
-77.05K
-1.13%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
7.55M
11.17%
-233.81K
-3.00%
Mar 31, 2025
Rubric Capital Management LP
6.14M
9.08%
+590.00K
+10.63%
Mar 31, 2025
Invesco Advisers, Inc.
3.60M
5.33%
+375.44K
+11.64%
Mar 31, 2025
AQR Capital Management, LLC
2.66M
3.93%
+1.85M
+230.30%
Mar 31, 2025
State Street Global Advisors (US)
2.19M
3.24%
-83.38K
-3.67%
Mar 31, 2025
ArrowMark Colorado Holdings, LLC
1.89M
2.8%
-84.96K
-4.30%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
1.82M
2.69%
+600.34K
+49.32%
Mar 31, 2025
American Century Investment Management, Inc.
1.59M
2.35%
+473.09K
+42.41%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: hace 9 horas
Actualizado: hace 9 horas
Nombre
Proporción
SPDR S&P Health Care Equipment ETF
1.7%
Invesco S&P SmallCap Health Care ETF
1.37%
First Trust Nasdaq Lux Digi Health Solutions ETF
0.63%
Ballast Small/Mid Cap ETF
0.41%
iShares S&P Small-Cap 600 Value ETF
0.3%
WisdomTree US SmallCap Quality Growth Fund
0.3%
SPDR S&P 600 Small Cap Value ETF
0.29%
Avantis US Small Cap Value ETF
0.28%
JPMorgan Fundamental Data Science Mid Core ETF
0.22%
iShares U.S. Medical Devices ETF
0.22%
Ver más
SPDR S&P Health Care Equipment ETF
Proporción1.7%
Invesco S&P SmallCap Health Care ETF
Proporción1.37%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proporción0.63%
Ballast Small/Mid Cap ETF
Proporción0.41%
iShares S&P Small-Cap 600 Value ETF
Proporción0.3%
WisdomTree US SmallCap Quality Growth Fund
Proporción0.3%
SPDR S&P 600 Small Cap Value ETF
Proporción0.29%
Avantis US Small Cap Value ETF
Proporción0.28%
JPMorgan Fundamental Data Science Mid Core ETF
Proporción0.22%
iShares U.S. Medical Devices ETF
Proporción0.22%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
